OncoMatch/Clinical Trials/NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Is NCT06742996 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Sonrotoclax and Zanubrutinib for mantle cell lymphoma.
Treatment: Sonrotoclax · Zanubrutinib — The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody-based immunotherapy or chemoimmunotherapy
Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy
Cannot have received: BCL2 inhibitor
Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)
Cannot have received: BTK degrader
Prior therapy with BTK degraders
Cannot have received: Bruton tyrosine kinase inhibitor
Exception: unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi
Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible.
Cannot have received: autologous stem cell transplantation
Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
Cannot have received: chimeric antigen receptor T-cell therapy
Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- Mayo Clinic Phoenix · Phoenix, Arizona
- Yale University, Yale Cancer Center · New Haven, Connecticut
- Memorial Cancer Institute, Memorial Healthcare System · Pembroke Pines, Florida
- Cleveland Clinic Florida · Weston, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06742996 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor, BTK degrader, Bruton tyrosine kinase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify